Lawsuits, Just the Cost of Criminal Marketing of Antipsychotic Drugs
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.”
-
-
“Much worse than Tuskegee…” More Revelations Re: U.S. Guatemala Experiment
"… it’s appalling — that, at the same time as the United States was prosecuting Nazi doctors for crimes against humanity, the U.S. government was supporting research that placed human subjects at enormous risk.”
-
US Apologizes for Criminal Human Experiment
Does an "apology" suffice for criminal experimentation designed to cause harm?
-
Former Sen Finance Committee Investigator Speaks Out
"What’s gone on with the pharmaceutical industry is a physician arms race to buy off doctors…"
-
Another Risk of Death Linked to Atypical Antipsychotics
"The risk was greater for individuals prescribed atypical rather than conventional drugs."
Antipsychotic Drugs and Risk of Venous Thromboembolism: Nested Case-Control Study BMJ -
NY Times Corrects Gina Kolata Re: Alzheimer’s
Five weeks after publishing a grossly dis-informative front-page report by Gina Kolata about Alzheimer’s research,The New York Times published a lengthy three paragraph correction.
-
FDA Urges Florida Not to Bar Foster Kids From Psych Drug Trials
How many children in foster care serve as human guinea pigs in commercial drug trials?
-
FDA Expands Market for Another Toxic Antipsychotic
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’…
-
Child’s Ordeal Shows Risks of Antipsychotic Drugs for Young
The prescribed drugs transformed Kyle Warren from a rambunctious healthy child into a drooling, sedated, obese, “shell.”
-
Research Integrity: Don’t Mess With the DSMB
"The current way that DSMBs are constituted and report has resulted in a loss of faith." NEJM
-
Globalization of Pediatric Drug Trials–For Whose Benefit?
There is no evidence to indicate that children have been the beneficiaries of the Pediatric Exclusivity Provision of FDAMA (enacted in 1998): there is evidence that pharmaceutical companies have increased their profits from the legislation by at least $14 billion.
-
Making a Killing–Marketing Exercises by Dr. Carl Elliott
The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research.